Harvest Portfolios Group Inc. Sells 7,046 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Harvest Portfolios Group Inc. trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 13.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,340 shares of the biopharmaceutical company's stock after selling 7,046 shares during the quarter. Regeneron Pharmaceuticals makes up 1.5% of Harvest Portfolios Group Inc.'s investment portfolio, making the stock its 26th largest position. Harvest Portfolios Group Inc.'s holdings in Regeneron Pharmaceuticals were worth $46,612,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also bought and sold shares of the company. Catalina Capital Group LLC lifted its holdings in Regeneron Pharmaceuticals by 13.6% in the 3rd quarter. Catalina Capital Group LLC now owns 343 shares of the biopharmaceutical company's stock worth $361,000 after buying an additional 41 shares during the period. Crestwood Advisors Group LLC raised its holdings in shares of Regeneron Pharmaceuticals by 18.4% during the third quarter. Crestwood Advisors Group LLC now owns 476 shares of the biopharmaceutical company's stock valued at $500,000 after acquiring an additional 74 shares in the last quarter. NorthRock Partners LLC lifted its stake in Regeneron Pharmaceuticals by 83.5% in the third quarter. NorthRock Partners LLC now owns 422 shares of the biopharmaceutical company's stock worth $444,000 after acquiring an additional 192 shares during the period. Amalgamated Bank boosted its holdings in Regeneron Pharmaceuticals by 6.4% in the third quarter. Amalgamated Bank now owns 22,820 shares of the biopharmaceutical company's stock valued at $23,989,000 after acquiring an additional 1,382 shares in the last quarter. Finally, United Advisor Group LLC increased its position in shares of Regeneron Pharmaceuticals by 68.9% during the third quarter. United Advisor Group LLC now owns 549 shares of the biopharmaceutical company's stock valued at $577,000 after buying an additional 224 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN traded down $12.78 during mid-day trading on Wednesday, hitting $816.65. 879,543 shares of the company traded hands, compared to its average volume of 520,916. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock's fifty day moving average price is $1,043.57 and its 200-day moving average price is $1,039.92. The firm has a market cap of $90.03 billion, a price-to-earnings ratio of 20.53, a price-to-earnings-growth ratio of 3.17 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a one year low of $783.57 and a one year high of $1,211.20.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm's stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 7.48% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of research reports. Evercore ISI decreased their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating for the company in a report on Thursday, October 24th. Truist Financial lowered their price target on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a "buy" rating for the company in a research report on Friday, November 1st. BMO Capital Markets cut their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an "outperform" rating on the stock in a research report on Friday, November 1st. Cantor Fitzgerald reiterated a "neutral" rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Finally, Leerink Partners restated a "market perform" rating and issued a $1,077.00 price objective (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $1,092.62.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.